BlackRock, Inc.

BlackRock insider buys 46,745 shares of ECAT at $16.34; 5th consecutive daily purchase within 6 days

BlackRock executed its fifth consecutive daily purchase of ECAT shares within a six-day window (2025-03-17 through 2025-03-24), accumulating 46,745 shares at $16.34 on the most recent transaction. This sustained buying pattern, coupled with the insider's cross-ticker track record of 13 prior buys, indicates persistent acquisition activity at this closed-end fund trust. However, context is limited: the current price of $16.35 shows minimal change from the transaction price, the stock trades 9.5% below its 52-week high of $18.07, and none of the five same-ticker trades yet have measurable 90-day outcomes. Without clarity on whether these purchases are discretionary or scheduled, and absent broader portfolio or fund performance context, the pattern suggests consistent interest but does not establish a clear directional signal.

BlackRock insider purchased 101,600 shares of ECAT at $16.20; now holds 1,176,800 shares (+9.4%)

BlackRock executed a purchase of 101,600 shares at $16.20 on 2025-03-21, increasing holdings by 9.4% to 1,176,800 shares. This transaction is part of a rapid accumulation pattern: the same insider made 5 consecutive daily purchases between 2025-03-14 and 2025-03-21 at this ticker. The stock is currently trading at $16.23, near the lower end of its 52-week range of $16.00–$18.07, and has declined 3.3% over the past 30 days and 3.1% over 90 days. The prior same-ticker purchases lack measurable 90-day outcome data, so cross-ticker timing cannot yet be assessed. The rapid succession of purchases at depressed price levels warrants tracking to determine whether this accumulation pattern reflects systematic positioning or scheduled activity.

BlackRock insider buys 101,600 shares of ECAT at $16.31; stock -10.2% from 52-week high after recent buy sequence

BlackRock purchased 101,600 shares of BlackRock ESG Capital Allocation Term Trust (ECAT) on 2025-03-20 at $16.31, adding to holdings that grew from 973,600 to 1,075,200 shares (+10.4%). This transaction is part of a concentrated buying pattern: five separate purchases occurred over five consecutive trading days (2025-03-13 through 2025-03-20). The current price of $16.22 is -10.2% from the 52-week high of $18.07 and down -3.3% over 30 days, establishing a backdrop of recent price weakness at the time of purchase. However, all five recent trades at ECAT remain too recent to measure 90-day outcomes, and the insider's broader cross-ticker track record shows 11 prior open-market buys with no quantified historical timing success data provided. The rapid accumulation sequence warrants monitoring to determine whether subsequent price action validates or contradicts this positioning.

BlackRock Inc. bought 101,600 shares of ECAT at $16.21 on 2025-03-19; stock now -10.2% from 52-week high.

BlackRock added 101,600 shares to its ECAT position, raising holdings from 872.0K to 973.6K shares. The purchase occurred at $16.21, with the security currently trading at $16.23, near its 52-week low range. This marks the fifth consecutive buy in ECAT over a 7-day span (2025-03-12 through 2025-03-19), suggesting a pattern of sustained accumulation. However, the timing context is constrained: the stock trades 10.2% below its 52-week high, and the insider's SAME-TICKER outcomes at ECAT remain unmeasurable (trades too recent for 90-day assessment), limiting conclusions about positioning accuracy at this specific security.

BlackRock insider buys 101,600 shares of ECAT at $16.12; 5 consecutive daily purchases in 8 days.

BlackRock purchased 101,600 shares of BlackRock ESG Capital Allocation Term Trust at $16.12 on 2025-03-18, increasing holdings from 770,400 to 872,000 shares. This transaction is part of an unusual pattern: the insider executed 5 consecutive buy transactions at ECAT between 2025-03-11 and 2025-03-18, with no measurable outcomes yet available for any of these recent trades. The current price of $16.08 sits 11.0% below the 52-week high and has declined 4.1% over the prior 30 days and 4.6% over 90 days. The systematic daily purchasing across this narrow window is the key signal; however, all five same-ticker trades remain too recent to evaluate execution quality relative to subsequent price movement.

BlackRock insider buys 101,600 shares of ECAT at $16.18; 5 consecutive buys in 6 days amid -5.6% 90-day decline

BlackRock's insider purchased 101,600 shares on 2025-03-17 at $16.18, increasing holdings by 15.2% to 770,400 shares total. This transaction is the sixth consecutive buy in six trading days (2025-03-10 through 2025-03-17), representing a pattern of sustained accumulation in a fund trading at -10.6% from its 52-week high and down 5.6% over the past 90 days. The current price of $16.16 is within the 52-week range ($16.00–$18.07), with no outcomes yet measurable from the prior five consecutive transactions. While the repeated purchases over such a short window merit attention, prior outcomes at this ticker are not yet observable, and cross-ticker timing data is not available to assess conviction history in comparable positions.

BlackRock insider buys 86,000 ECAT shares at $16.16; holding now 668,800 shares (+14.8% increase).

BlackRock purchased 86,000 shares of BlackRock ESG Capital Allocation Term Trust (ECAT) at $16.16 on March 14, 2025, increasing holdings to 668,800 shares. The purchase occurred as the security trades at $16.00, down 11.5% from its 52-week high and 8.9% lower over the past 90 days. This represents the fifth consecutive purchase within four calendar days (March 7, 10–14), suggesting a pattern of repeated acquisition at declining prices. However, all five of these same-ticker purchases remain too recent to assess 90-day outcomes, and no comparable historical track record exists at this specific ticker to establish whether prior similar patterns proved prescient or mistaken.

BlackRock insider bought 86,000 shares of ECAT at $16.41 on 2025-03-13, expanding stake to 582,800 shares (+17.3%).

BlackRock's insider purchased 86,000 shares (86.0K shares) at $16.41 on 2025-03-13, increasing holdings by +17.3% from 496,800 shares to 582,800 shares for a total value of $1,411,260.00. This purchase occurs within a streak of five consecutive daily buys at ECAT (2025-03-06 through 2025-03-12), suggesting sustained accumulation rather than a one-off transaction. The current price of $16.33 sits -9.6% from the 52-week high of $18.07, placing the trust in a moderately depressed zone relative to recent peaks, though none of the insider's prior same-ticker transactions have yet reached measurable 90-day outcomes. The pattern merits monitoring to discern whether this concentrated buying reflects a deliberate accumulation strategy or adherence to a predetermined schedule.

BlackRock bought 86,000 shares of ECAT at $16.43 on 2025-03-12, raising holdings 20.9% to 496,800 shares

BlackRock purchased 86,000 shares at $16.43, a substantial 20.9% increase to total holdings of 496,800 shares. The transaction occurred at a price -9.0% below the 52-week high of $18.07, and follows five consecutive buys of the same security within a 7-day window (2025-03-05 through 2025-03-12). The timing and scale of these clustered purchases warrant attention, though the outcome of prior same-ticker trades cannot yet be evaluated. Current price of $16.44 is essentially unchanged from the transaction price, with the stock down 2.8% over 30 days and 6.2% over 90 days from the purchase dates.

BlackRock insider bought 86,000 shares of ECAT at $16.24 on 2025-03-11, expanding holdings +26.5% to 410,800 shares.

BlackRock, Inc. (insider) purchased 86,000 shares of BlackRock ESG Capital Allocation Term Trust at $16.24 on 2025-03-11, a transaction valued at $1,396,640.00 that increased holdings from 324,800 shares to 410,800 shares. This purchase is part of a four-day buying pattern at ECAT (2025-03-05, 2025-03-06, 2025-03-07, 2025-03-10), though measurable performance outcomes for those prior same-ticker trades are not yet available. The current price of $16.21 reflects modest recent weakness (-3.5% over 30 days, -8.3% over 90 days, and -10.3% from the 52-week high of $18.07), positioning the transaction near the lower end of the 52-week range of $16.04–$18.07. The cross-ticker track record shows 4 prior buys with no measurable timing outcomes yet recorded at this ticker, limiting direct comparison to prior insider activity.